<DOC>
	<DOC>NCT00477334</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of single-day famciclovir episodic treatment in Black patients with recurrent genital herpes</brief_summary>
	<brief_title>Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients</brief_title>
	<detailed_description />
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Famciclovir</mesh_term>
	<mesh_term>2-Aminopurine</mesh_term>
	<criteria>Black men or women 18 years or older History of recurrent genital herpes with at least 4 recurrences in preceding 12 months or in preceding 12 months prior to using suppressive antiviral therapy Documented herpes simplex virus type 2 (HSV2) seropositivity Willingness to discontinue suppressive therapy during study, if applicable Willingness and ability to comply with the study protocol Pregnant or breastfeeding women Women of childbearing potential not using accepted methods of contraception Hypersensitivity to famciclovir or drugs with similar chemical structures Renal dysfunction Known or suspected to have decompensated liver disease Known to have gastrointestinal malabsorption Known to be immunocompromised Known to be hypersensitive to ingredients in study medication Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Recurrent genital herpes</keyword>
	<keyword>Black population</keyword>
</DOC>